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A llogeneic hematopoietic stem cell transplantation (HSCT) is widely performed to treat many hema-
tological malignancies,  and a number of patients have 
now survived for years post-transplantation.  However,  
allogeneic HSCT is frequently complicated by graft-
versus-host disease (GVHD).  GVHD can be divided into 
acute and chronic disease; chronic GVHD develops in 
approximately half of all long-term survivors of alloge-
neic HSCT ［1］.  Although steroids remain the standard 
initial treatment for chronic GVHD,  and although half 
of all patients respond to ﬁrst-line treatment,  ste-
roid-refractory chronic GVHD,  especially generalized 
scleroderma,  has a poor prognosis.  Chronic GVHD is 
currently the leading cause of long-term morbidity and 
mortality following allogeneic HSCT ［1-4］.
　 The pathogenesis of chronic GVHD remains elu-
sive,  but recent studies have provided some insights 
［4,5］.  Donor T cells play a central role in the immu-
nological attack of host tissues seen in both acute and 
chronic GVHD.  It was traditionally assumed that the 
predominant cytokines produced during acute GVHD 
are Th1 cytokines,  whereas those produced during 
chronic GVHD are Th2 cytokines ［6］.  In addition to 
Th2 cells,  recent studies have suggested that multiple 
cytokines secreted by Th1 and Th17 cells are involved 
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Chronic graft-versus-host disease (GVHD) is a major cause of late death and morbidity following allo-
geneic hematopoietic cell transplantation (HSCT). Retinoic acid (tamibarotene) exerts multiple eﬀects 
on cell diﬀerentiation and is clinically used for the treatment of acute promyelocytic leukemia. 
Tamibarotene down-regulates both Th1 and Th17 diﬀerentiation in donor T cells after allogeneic 
HSCT, resulting in attenuation of experimental chronic GVHD. Based on preclinical data, we have 
launched a phase II study of tamibarotene in patients with steroid-refractory chronic GVHD. This 
study will clarify whether tamibarotene can exert beneﬁcial eﬀects in patients with steroid-refractory 
chronic GVHD. 
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in the pathogenesis of chronic GVHD ［7-10］.
　 Retinoid exerts multiple eﬀects on cell diﬀerentia-
tion and survival by binding to retinoic acid receptors 
(RARs) and retinoid X receptors ［11］.  Retinoic acids,  
such as all-trans-retinoic acid (ATRA) and tamibaro-
tene (Am80),  speciﬁcally target acute promyelocytic 
leukemia (APL) blasts in vivo and are clinically used 
as treatments for APL.  In addition,  retinoids can 
suppress Th17 cell diﬀerentiation with reciprocal 
induction of T regulatory cells ［12］.  Tamibarotene,  a 
novel RARα/β-speciﬁc synthetic retinoid,  is approxi-
mately 10-fold more potent than ATRA and directly 
inhibits Th1 cytokine production ［13,14］.  We previ-
ously reported in an experimental mouse model that 
tamibarotene down-regulated both Th1 and Th17 dif-
ferentiation in donor T cells,  resulting in attenuation 
of chronic GVHD ［8］.  In the cited study,  tamibaro-
tene exhibited beneﬁcial eﬀects in terms of both the 
prevention and treatment of chronic GVHD.
　 Based on this background,  we have launched an 
open-labeled,  multicenter phase II study of tamibaro-
tene in patients with steroid-refractory chronic GVHD.
Endpoints
　 The primary endpoints are the probability of fail-
ure-free survival (FFS) ［15,16］ and the complete/
partial response rates at 24 weeks.  Complete/partial 
responses will be assessed using the criteria of the 
National Institutes of Health (NIH) ［17］.  FFS will be 
deﬁned by the absence of all of the following: any 
change in treatment,  non-relapse mortality,  and recur-
rent malignancy during the initial systemic treatment.  
Secondary outcome measures include the probability 
of FFS and the complete/partial response rates at 12 
weeks,  the probability of FFS and overall survival at 
1 year after completion of 24 weeks treatment and the 
proportion of patients with FFS who exhibit at least 
a 50  reduction in the baseline steroid dose required 
at 24 weeks.
Study Design
　 This is a multicenter,  prospective,  non-random-
ized,  trial to clarify whether tamibarotene can exert 
beneﬁcial eﬀects in patients with steroid-refractory 
chronic GVHD; no consensus has yet been attained on 
the optimal agents for secondary treatment of chronic 
GVHD.  Six facilities are participating in this study.  
(Trial registration number: UMIN registration num-
ber: 000020363)
Eligibility Criteria
　 All patients who meet the principal inclusion and 
exclusion criteria will be invited for screening.  The 
principal inclusion and exclusion criteria are listed in 
Table 1.  Written informed consent must be obtained 
by an investigator before any screening or inclusion 
procedure is conducted.  This study is conducted in 
compliance with the principles of the Declaration of 
Helsinki,  and the protocol has been approved by the 
institutional review board of each participating hospi-
tal.  (Local Ethics Committee Board approval num-
ber: 250201)
Treatment Methods
　 The investigational agent,  tamibarotene,  is kindly 
provided by Toko Pharmaceutical Industrial Co.,  Ltd.  
Patients take tamibarotene orally (4 mg/day) for 24 
weeks.  If any unexpected adverse events with Grade 2 
or expected adverse events with Grade 3 develop,  the 
daily dose will be decreased to 2 mg/day,  2 mg every 
other day,  or discontinued.  The Common Terminology 
Criteria for Adverse Events version 4.0 indicate that 
patients with grade 3 liver dysfunction prior to regis-
tration,  caused by chronic GVHD,  can be treated 
without dose reduction or discontinuation.  If the 
adverse events are mild (grade 0-1),  the daily dose can 
be increased to 8 mg/day 4 weeks after the start of 
therapy.  If a suﬃcient therapeutic eﬀect is observed 
before the end of treatment,  a maintenance dose of 
2 mg/day until the end of the treatment is permitted.
　 Recurrent malignancy will be deﬁned as hematolog-
ical relapse or any unplanned intervention to prevent 
progression of malignancy in patients with molecular,  
cytogenetic,  ﬂow cytometric,  or any other evidence of 
malignant disease after transplantation ［15,16］.
Sample Size
　 We assume the lower limit of interest to be 20  
and the expected response rate to be 50  using histor-
ical control data on the rate of response to existing 
secondary treatments for chronic GVHD ［18-27］.  
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Using Simonʼs two-stage design model,  we calculate 
that p0 = 0.2,  pa = 0.5,  ﬁrst type I error (α) = 0.05 
(one-sided),  and second type I error (β) = 0.2.  This 
yields an accrual number of 18 patients,  using the 
normal approximation to the binomial distribution.  
Interim Analysis
　 An interim analysis for inferiority will be per-
formed once the ﬁrst 9 patients are evaluable for pri-
mary endpoints.  If,  at the time of this interim analysis,  
two or less patients were found to have achieved FFS 
and the complete/partial response,  the data and safety 
monitoring board will recommend early trial closure.
Discussion
　 Retinoids have been used to treat a variety of der-
matological conditions,  including scleroderma ［28-
30］.  Because the skin manifestations of scleroderma 
are clinically and histologically similar to those of 
sclerodermatous chronic GVHD,  retinoids have been 
used to treat chronic GVHD ［31-33］.  Marcellus et al.  
retrospectively evaluated the eﬃcacy of a synthetic 
retinoid,  etretinate,  in 32 patients with refractory 
sclerodermatous chronic GVHD ［32］.  Clinical 
responses were assessed after 3 months of therapy,  
and 20 of 27 evaluable patients exhibited an improve-
ment,  including softening of the skin,  ﬂattening of 
cutaneous lesions,  increased range of motion,  and 
improved performance status.  Many patients suﬀered 
skin breakdown and/or ulceration during therapy,  
leading to drug discontinuation in 6 patients.
　 As tamibarotene has little aﬃnity for RARγ,  fewer 
adverse eﬀects related to occupation of this receptor 
are expected compared with those caused by other 
retinoids,  including etretinate.  Although retinoids 
have been shown to inhibit the proliferation of normal 
human skin ﬁbroblasts in vitro and to reduce collagen 
production,  the precise mechanism of action of etreti- 
nate remains poorly understood ［34-36］.  A study in 
an experimental mouse model revealed the mechanism 
of action of tamibarotene ［8］.  Tamibarotene sup-
presses Th1 and Th17 responses and TGF-β expres-
sion in the skin,  which are involved in the pathogenesis 
of chronic GVHD.  Our planned study will clarify 
whether tamibarotene can safely exert beneﬁcial eﬀects 
in patients with steroid-refractory chronic GVHD.
　 Many diﬀerent agents have been used as secondary 
treatments for chronic GVHD.  However,  the lack of 
standardized,  validated response criteria has been a 
major obstacle when designing and interpreting clinical 
trials of such treatments.  In the cited study on etreti-
nate,  Marcellus et al.  assessed clinical responses in a 
unique manner.  In eﬀorts to unify response evaluations,  
the 2005 NIH Consensus Conference proposed new 
criteria for measurement of responses in clinical trials 
［17］,  and Inamoto et al.  suggested FFS to be a mean-
ingful endpoint for such trials ［15,16］.  In the planned 
study,  the probability of FFS,  and complete/partial 
responses assessed using the NIH criteria,  will serve 
as the primary endpoints.  To reduce the risk of ste-
roid-related adverse events,  we will also measure the 
proportion of patients who exhibit at least a 50  reduc-
tion in the required baseline steroid dose at 24 weeks.
　 We believe that this study will signiﬁcantly con-
tribute to the evolution of new secondary treatments 
for chronic GVHD.
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